麻豆传媒

Ciprofloxacin and celecoxib formulation aims to target several ALS mechanisms

Half of patients had no evidence of disease activity at 48 weeks

Data suggest clinical response with few adverse effects for patients

Topline data show where sodium phenylbutyrate and taurursodiol fell short

At 48 weeks, atogepant showed consistent safety profile and efficacy

Exon-skipping therapy was well-tolerated, phase II data showed

Hospitalized patients with seizure burden of at least 50% had poor outcomes

Findings may point to novel biomarker

No negative effects on early infant development or health seen

Prevalence greater than normal aging, but not as high as Parkinson's disease

Findings highlight importance of early screening for apnea, researcher says

Simazine, atrazine, lindane in the Rocky Mountain and Great Plains region emerge in new analysis

New trial focuses on drug's performance in spinal muscular atrophy beyond childhood

Trial's long-term follow-up fills gap left from primary analysis